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were $Brz674.527 for each 100 treated patients, when comparing the group of 
patients that received tocilizumab to the group of patients that did not receive tocili-
zumab. CONCLUSIONS: Findings suggest tocilizumab has the potential to offer costs 
reductions in the public health care system in Brazil.
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OBJECTIVES: To develop a cost-effectiveness and budget impact analysis of intra-
articular sodium hyaluronate 25 mg/2.5 ml (SH) versus total knee arthroplasty (TKA) 
in the treatment of knee osteoarthritis grades II and III of Kellgren-Lawrence classiﬁca-
tion, in patients who failed conservative treatment, under the Brazilian public health 
care system (BPHS) perspective. METHODS: A Markov model was developed to 
project costs and outcomes associated with knee osteoarthritis progression in 3 years. 
In the model all patients were eligible to surgery and could either receive SH or 
undergo TKA immediately. SH could delay or cancel surgery. The cycle duration was 
3 months and the corresponding transition probabilities were obtained from the litera-
ture. The outcome was expressed as the number of avoided TKAs. The analysis con-
sidered only direct medical costs, including drugs, physician visits, procedures and 
complications treatment. Costs and outcomes were discounted at 5% per year. A 
budget impact analysis was developed considering the estimated number of TKAs in 
the BPHS in 2009. Main parameters were evaluated in a sensitivity analysis. RESULTS: 
In a 3-year time horizon, total costs per patient were US$3445 (2005-PPP-index 
USD1.0  R$1.4) for the SH group and R$4381 for the TKA group. The reduction 
in the absolute number of surgeries was 72.8% in the SH group, compared with TKA. 
Likewise, there was a cost reduction of US$936, in favor of SH. Considering 3991 
eligible patients in the public system, the total annual costs for SH and TKA groups 
were US$5,136,234 and US$17,484,003, respectively. As a result, the budget impact 
was US$12,347,769, in favor of SH. The sensitivity analysis about the time horizon 
showed a cost-saving result until 4 years. CONCLUSIONS: The use of SH after failure 
of conservative treatment in patients with grades II or III knee osteoarthritis showed 
to be effective, leading to a reduction in costs and number of surgeries.
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OBJECTIVES: To estimate the budget impact implied by the introduction of RTX 
after failure of one or more TNF a therapies for the French health care system. 
METHODS: A Markov model reproduced the course, over 4 years, of patients treated 
by either inﬂiximab, etanercept, adalimumab or RTX, after failure of one or more 
TNF a therapies. Markov states were composed of the 4 TNF a strategies. The success 
rate for each strategy (ACR20) was based on a bayesian mixed treatment comparisons 
model.Health care consumptions were estimated from an observational study con-
ducted retrospectively in 59 hospital rheumatology services (TC2 study). Three 
hypotheses were tested for the penetration of RTX into the market: RTX is not used 
(H1), RTX is used progressively (H2), RTX is the only treatment available (H3). As a 
sensitivity analysis, we applied coefﬁcients to health care resources in third line. 
RESULTS: The RTX target population is expected to be 5700 patients. Under H1, 
direct total medical costs are expected to be a47,180,000. Under H3 these costs reach 
a32,600,000, thus a decrease of 31% respectively compared to H1. Under H2, costs 
progressively decreased as RTX penetrates the market. The impact of multiplication 
coefﬁcients is important. At the beginning of the simulation, the difference between 
the base-case analysis (H2) and the worst case sensitivity analysis (coeff2  20%) 
 concerning the total direct medical costs reached a3,160,000 (respectively a47,560,000 
for H2 and a50,720,000 for H2–20%). However, while RTX progressively enters into 
the market, this difference decreases, attaining only a1,175,000 at the end of the simu-
lation. CONCLUSIONS: RTX is expected to produce important savings if used after 
failure of one or more TNF a therapies. This is due to the administration rhythm of 
this product, generally every 6 to 12 months.
PMS22
A COST-OF-ILLNESS STUDY OF PSORIATIC ARTHRITIS IN SPAIN
Moreno JC1, Daudén E2, Rodriguez-Valverde V3, Gomez-Reino J4, Gratacos J5, Sabater FJ6, 
Casado MA7
1Hospital Reina Sofía, Córdoba, Andalucía, Spain, 2Hospital La Princesa, Madrid, Spain, 
3Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, 4Complexo 
Hospitalario Universitario, Santiago de Compostela, Galicia, Spain, 5Hospital Parc Taulí, 
Sabadell, Cataluña, Spain, 6Schering-Plough S.A, Alcobendas, Spain, 7Pharmacoeconomics & 
Outcomes Research Iberia, Madrid, Spain
OBJECTIVES: To estimate the annual direct and indirect costs of psoriatic arthritis 
(PsA) in Spain, and to identify key cost drivers. METHODS: An observational study 
was undertaken at 18 Spanish centres. Sociodemographic characteristics and duration 
of the disease were collected from patient hospital clinical records, and PsA-related 
resources (a, year 2008 values) from patient notebooks. The following direct resources 
were collected: inpatient hospitalisations, surgeries, outpatient visits (specialists, 
general care physician, other health care professionals and alternative medicine), 
diagnostic procedures, laboratory tests, medication (prescription -including TNFalpha 
inhibitors administered at hospital- and non-prescription drugs paid by patients), 
hospital day-care facilities for the administration of biological therapies and photo-
therapy sessions. Indirect resources consisted of productivity losses (full or part-time), 
social assistance and out-of-pocket expenses paid directly by patients (formal caregiv-
ers, disease-related investments). RESULTS: Data were available on 287 patients with 
PsA. The mean age was 52.40 o 12.53 years, 55.7% were men, and the mean disease 
duration was 10.85 o 9.62 years. Of these patients, 24.7% had received biologic 
therapy during the study period. The average annual cost per patient with PsA was 
a6710 (95% conﬁdence interval [CI], a4949, a8584). Direct and indirect costs repre-
sented a5449 (95%CI, a4367–a6597, 81.2% of total costs) and a1261 (95%CI, 
a581–a1987, 18.8% of total costs), respectively. The most important categories of 
costs were for medication (a3,758, 95%CI, a3,338–a4,241, 56.0% of total costs), 
productivity losses (a1121, 95%CI, a551–a1692, 16.7% of total costs), visits (a750, 
95%CI, a507–a943, 11.2% of total costs), and hospital day visits (a306, 95%CI, 
a289–a324, 4.6% of total costs). CONCLUSIONS: Our data show that psoriatic 
arthritis is associated with a remarkable impact over society in Spain, with a mean 
annual cost per patient of a6710. Direct costs represent 81.2% of total costs.
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OBJECTIVES: Neuromuscular disorders (NMDs) are chronic devastating diseases. 
The objective of this multicenter cross-sectional study was to evaluate cost of illness 
in three NMD in Germany. METHODS: A cohort of 107 patients with Amyotrophic 
Lateral Sclerosis (ALS, n  46), Facioscapulohumeral Muscular Dystrophy (FSHD, n 
 20) or Myasthenia Gravis (MG, n  41) were recruited consecutively in seven centers 
in Germany. The health-economic data were collected using a “bottom-up” approach 
consisting of comprehensive questionnaires and patient diaries. Bootstrap 95% conﬁ-
dence intervals were calculated for cost data. Cost-driving factors were identiﬁed using 
multivariate regression analysis with standard errors estimated using a bootstrap 
technique. Costs were evaluated from the German societal perspective in 2009 Euros 
(EUR). RESULTS: Total annual costs from the societal perspective were EUR 36,380 
(95% CI: 27,090–47,970) per patient in ALS, a26,240 (95% CI: 17,770–37,940) in 
FSHD and a14,950 (95% CI: 10,470–21,730) in MG. The main components of costs 
were the expenditures of health insurance and the loss of productivity of patients and 
their caregivers. Following independent cost-driving factors were identiﬁed in ALS: 
disease severity, assistance in activities of daily living (ADL), dementia and younger 
age. In FSHD, they were disease severity and assistance in ADL. Cost-drivers in MG 
were disease severity and assistance in ADL. CONCLUSIONS: Socioeconomic burden 
of NMDs in Germany is considerable. ALS was associated with highest costs among 
studied NMDs. Further studies evaluating both the health-economic and clinical 
effects of NMDs treatment as well as disease-management programs and benchmark-
ing activities are necessary.
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OBJECTIVES: Costs of Spina Biﬁda (SB) and of its prevention with folic acid have 
never been estimated in Italy. We carried out a 12-month observational multicentre, 
prospective, cost-of-illness study of the to assess direct and indirect costs of SB from 
the patient, the third-party payer (National Health Service- NHS) and the societal 
perspective. METHODS: A total of 130 patients were enrolled in this study and were 
eligible to be analyzed according to the study protocol during 2008. The study was 
conducted in three Italian centres (Milan, Rome and Parma). Inclusion criteria were: 
walking with motor impairment, walking with simple aid, walking with complex aid, 
non walking. Exclusion criteria were: patients with dorsal lesion up to D5/D6, patients 
with spina biﬁda aperta with severe comorbidity RESULTS: Mean age was 13 years 
(min.0 – max. 29 years). The mean total cost for SB, including direct and indirect 
items, was a11,351 per patient per year (58% direct cost and 42% on indirect cost). 
The cost of medical device for SB represents the most signiﬁcant item, accounting for 
38% of the total expenses. Difference on cost analysis was observed per age (a13,882 
for an age between 0–4 years), per SB severity (non walking,, a14,323) and per lesion 
(a12,103 for SB aperta). The average Cost-of-illness per year in Italy was evaluated 
in 60 million of euro. CONCLUSIONS: The estimate of the socio-economic burden 
of SP may encourage health care interventions to prevent the occurrence of the disease 
